Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 10

1.

Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer.

Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, Grénman R, Minn H.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):971-82. Erratum in: Int J Radiat Oncol Biol Phys.2004 Nov 1;60(3):1010.

PMID:
15234030
2.

18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies.

Tolvanen T, Lehtiö K, Kulmala J, Oikonen V, Eskola O, Bergman J, Minn H.

J Nucl Med. 2002 Dec;43(12):1674-80.

3.

Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET.

Lehtiö K, Oikonen V, Grönroos T, Eskola O, Kalliokoski K, Bergman J, Solin O, Grénman R, Nuutila P, Minn H.

J Nucl Med. 2001 Nov;42(11):1643-52.

4.

Pharmacokinetics of [18F]FETNIM: a potential marker for PET.

Grönroos T, Eskola O, Lehtiö K, Minn H, Marjamäki P, Bergman J, Haaparanta M, Forsback S, Solin O.

J Nucl Med. 2001 Sep;42(9):1397-404.

5.
6.

The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model.

Chung JK, Chang YS, Lee YJ, Kim YJ, Jeong JM, Lee DS, Jang JJ, Lee MC.

Ann Nucl Med. 1999 Oct;13(5):303-8.

PMID:
10582799
7.

Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.

Hodgkiss RJ.

Anticancer Drug Des. 1998 Sep;13(6):687-702. Review.

PMID:
9755725
8.

Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.

Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA.

Radiology. 1995 Mar;194(3):795-800.

PMID:
7862981
9.

Nitroimidazoles and imaging hypoxia.

Nunn A, Linder K, Strauss HW.

Eur J Nucl Med. 1995 Mar;22(3):265-80. Review.

PMID:
7789400
10.

Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.

Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, Krohn KA.

Radiat Res. 1987 Aug;111(2):292-304.

PMID:
3628717

Supplemental Content

Support Center